New Cancer Drugs · global
AI-Designed Cancer Drug Reaches the Human Data Hurdle: Phase 1 Results for Pan-TEAD Inhibitor to Be Unveiled at ESMO
ISM6331 targets TEAD transcription factors downstream of the Hippo signaling pathway, and its first-in-human trial has been selected for an ESMO rapid oral presentation. However, its safety, dosing, and antitumor efficacy remain undisclosed, and the real clinical test will come when the data are presented in October.
A small-molecule cancer drug designed with the assistance of generative artificial intelligence is about to face a more practical test than the “AI drug discovery” label. Insilico Medicine announced that data from the first-in-human Phase 1 trial of the pan-TEAD inhibitor ISM6331 have been selected for a rapid oral presentation at the European Society for Medical Oncology (ESMO) 2026 Congress. The full clinical results are scheduled to be presented in Madrid on October 25.
ISM6331 targets the TEAD family of transcription factors. TEAD is downstream of the Hippo signaling pathway and helps regulate cell proliferation, survival, and tissue homeostasis. When this control system becomes dysregulated, it may contribute to tumor growth and the development of treatment resistance. “Pan-TEAD” inhibition is intended to suppress multiple TEAD family members simultaneously rather than target a single subtype. However, whether sufficient inhibition can be achieved in humans without disrupting normal tissue function remains a question for clinical data to answer.
The company said that ISM6331 was discovered and designed using its generative AI drug design platform, Chemistry42. AI’s specific role in this process was to help search for and optimize chemical structures with the desired properties; it cannot replace subsequent pharmacology, toxicology, and human trials. The significance of the presentation’s selection therefore lies not in another declaration that computers can generate molecules, but in the fact that this molecule has reached the stage at which patient data can be used to assess its safety and preliminary efficacy.
ClinicalTrials.gov registration data show that NCT06566079 is an open-label, multicenter, first-in-human Phase 1 study sponsored by InSilico Medicine Hong Kong Limited that enrolls patients with advanced or metastatic malignant mesothelioma and other solid tumors. The trial includes dose-escalation and dose-selection optimization components, with objectives covering safety, tolerability, pharmacokinetics, pharmacodynamics, the recommended Phase 2 dose, and preliminary antitumor activity.
Malignant mesothelioma is often associated with asbestos exposure, is frequently advanced at diagnosis, and has limited treatment options. Some mesotheliomas and other solid tumors also have abnormalities in the Hippo pathway, making TEAD a biologically grounded target that nevertheless poses considerable drug-development challenges. A small molecule must balance potency, selectivity, in vivo exposure, and an acceptable safety margin; binding to the target does not necessarily mean it can become an effective drug.
At this stage, neither the company nor the trial registry has disclosed the number of participants, dose levels, adverse events, extent of tumor shrinkage, or duration of efficacy. Selection for a rapid oral presentation means the study has secured a place on the conference program; it does not mean efficacy has been established. When the data are disclosed in October, the key questions will be the dose-limiting toxicities, treatment discontinuations, whether drug exposure aligns with target inhibition, and in which cancer types and among patients with which molecular characteristics any tumor responses occurred.